OBJECTIVES: To assess the total systemic antiviral use in Europe and to identify the antiviral substances most commonly used. METHODS: Within the European Surveillance of Antimicrobial Consumption (ESAC; www.esac.ua.ac.be), using the anatomical therapeutic chemical (ATC) classification and defined daily dose (DDD) measurement unit, data on total (out- and inpatient) systemic antiviral use (ATC J05), aggregated at the level of the active substance, were collected for 2008, and use was expressed in DDD (WHO ATC/DDD, version 2010) per 1000 inhabitants per day (DID). Antiviral substances were grouped according to their main indication. RESULTS: In Europe, 12 countries (Belgium, Croatia, Denmark, Estonia, Finland, France, Hungary, Italy, Luxembourg, Russia, Slovenia and Sweden) provided total (out- and inpatient) data and 4 countries (Austria, the Netherlands, Portugal and Norway) provided outpatient data only. Total systemic antiviral use varied by a factor of 10.95 between the country with the highest (3.53 DID in France) and the country with the lowest (0.32 DID in Croatia) use. HIV/AIDS antivirals represented more than 50% of the total antiviral use in most countries. The amount and spectrum of antivirals used varied greatly between countries. CONCLUSIONS: Our study demonstrated a wide variation of total systemic antiviral use in several European countries, as striking as that of outpatient systemic antibiotic, antimycotic and antifungal use. The variation is mainly determined by the use of HIV/AIDS antivirals. These observations should stimulate further analysis to understand the variation of specific antiviral substances. The ESAC data facilitate auditing of antiviral prescriptions and evaluation of the implementation of guidelines and public health policies.
OBJECTIVES: To assess the total systemic antiviral use in Europe and to identify the antiviral substances most commonly used. METHODS: Within the European Surveillance of Antimicrobial Consumption (ESAC; www.esac.ua.ac.be), using the anatomical therapeutic chemical (ATC) classification and defined daily dose (DDD) measurement unit, data on total (out- and inpatient) systemic antiviral use (ATC J05), aggregated at the level of the active substance, were collected for 2008, and use was expressed in DDD (WHO ATC/DDD, version 2010) per 1000 inhabitants per day (DID). Antiviral substances were grouped according to their main indication. RESULTS: In Europe, 12 countries (Belgium, Croatia, Denmark, Estonia, Finland, France, Hungary, Italy, Luxembourg, Russia, Slovenia and Sweden) provided total (out- and inpatient) data and 4 countries (Austria, the Netherlands, Portugal and Norway) provided outpatient data only. Total systemic antiviral use varied by a factor of 10.95 between the country with the highest (3.53 DID in France) and the country with the lowest (0.32 DID in Croatia) use. HIV/AIDS antivirals represented more than 50% of the total antiviral use in most countries. The amount and spectrum of antivirals used varied greatly between countries. CONCLUSIONS: Our study demonstrated a wide variation of total systemic antiviral use in several European countries, as striking as that of outpatient systemic antibiotic, antimycotic and antifungal use. The variation is mainly determined by the use of HIV/AIDS antivirals. These observations should stimulate further analysis to understand the variation of specific antiviral substances. The ESAC data facilitate auditing of antiviral prescriptions and evaluation of the implementation of guidelines and public health policies.
Authors: Karin Wiedenmayer; Eva Ombaka; Baraka Kabudi; Robert Canavan; Sarah Rajkumar; Fiona Chilunda; Selemani Sungi; Manfred Stoermer Journal: BMC Health Serv Res Date: 2021-03-24 Impact factor: 2.655
Authors: Mingliang Chen; Odile B Harrison; Holly B Bratcher; Zhiyan Bo; Keith A Jolley; Charlene M C Rodrigues; James E Bray; Qinglan Guo; Xi Zhang; Min Chen; Martin C J Maiden Journal: Emerg Infect Dis Date: 2021-04 Impact factor: 6.883
Authors: Nicolay Jonassen Harbin; Karin Rystedt; Morten Lindbaek; Ruta Radzeviciene; Johan Westin; Ronny Gunnarsson; Christopher C Butler; Alike W van der Velden; Theo J Verheij; Pär-Daniel Sundvall Journal: Scand J Prim Health Care Date: 2021-12-01 Impact factor: 3.147
Authors: Adriana Ariza; Cristobalina Mayorga; Gádor Bogas; Francesco Gaeta; María Salas; Rocco L Valluzzi; Marina Labella; Natalia Pérez-Sánchez; Cristiano Caruso; Ana Molina; Tahia D Fernández; María José Torres; Antonino Romano Journal: Int J Mol Sci Date: 2022-06-23 Impact factor: 6.208
Authors: Barbara Michiels; Karolien Van Puyenbroeck; Veronique Verhoeven; Etienne Vermeire; Samuel Coenen Journal: PLoS One Date: 2013-04-02 Impact factor: 3.240
Authors: Emily Bongard; Alike W van der Velden; Johanna Cook; Ben Saville; Philippe Beutels; Rune Munck Aabenhus; Curt Brugman; Slawomir Chlabicz; Samuel Coenen; Annelies Colliers; Melanie Davies; Muireann De Paor; An De Sutter; Nick A Francis; Dominik Glinz; Maciek Godycki-Ćwirko; Herman Goossens; Jane Holmes; Margareta Ieven; Menno de Jong; Morten Lindbaek; Paul Little; Frederico Martinón-Torres; Ana Moragas; József Pauer; Markéta Pfeiferová; Ruta Radzeviciene-Jurgute; Pär-Daniel Sundvall; Antoni Torres; Pia Touboul; Dionyssios Varthalis; Theo Verheij; Christopher C Butler Journal: BMJ Open Date: 2018-07-12 Impact factor: 2.692